<link rel='stylesheet' href='https//fonts.googleapis.com/css?family=Roboto:400,500,700,400italic|Material+Icons'>
Open Search
ARWR
Arrowhead
$
()


  • Ionis Pharmaceuticals just upgraded at Bernstein, here's why

    6/14/2024 - 05:28am
  • Instacart, Boston Beer upgraded: Wall Street's top analyst calls

    6/5/2024 - 09:51am
  • Arrowhead initiated with neutral view at Goldman Sachs, here's why

    6/5/2024 - 04:41am
  • Arrowhead announces topline results from PALISADE study

    6/3/2024 - 07:33am
  • Arrowhead announces results from ARCHES-2 study

    5/29/2024 - 05:38am
  • Arrowhead presents new Phase 2 Data of plozasiran in hyperlipidemia

    5/28/2024 - 06:07am
  • Arrowhead announces new interim clinical data on ARO-RAGE

    5/20/2024 - 06:04am
  • Arrowhead price target lowered by $9 at Morgan Stanley, here's why

    5/13/2024 - 08:34am
  • Arrowhead price target lowered by $5 at Citi, here's why

    5/10/2024 - 06:47am
  • Arrowhead reports Q2 EPS ($1.02), consensus (16c)

    5/9/2024 - 16:10pm
  • Arrowhead earns $50M milestone from Royalty Pharma

    5/2/2024 - 16:05pm
  • Arrowhead begins Phase 1/2a study of ARO-CFB for mediated kidney disease

    4/24/2024 - 07:38am
  • Athira Pharma appoints Javier San Martin as Chief Medical Officer

    4/15/2024 - 07:03am
  • Arrowhead announces new Phase 2 SHASTA-2 study of plozasiran in SHTG

    4/7/2024 - 09:12am
  • Arrowhead begins EAP to avail plozasiran outside of trials for patients with FCS

    3/25/2024 - 08:06am
dynamic_feed Breaking News